Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Aim: To evaluate the efficacy and tolerability of lapatinib (L) and intravenous vinorelbine (V) in patients with metastatic HER2-positive breast cancer who have previously received two lines of anti-HER2 therapy (i.e. trastuzumab [T] with chemotherapy and lapatinib with capecitabine [LC]). Method: C...

Full description

Bibliographic Details
Main Authors: Chan, Arlene, Shannon, C., De Boer, R., Baron-Hay, S., Redfern, A., Bauwens, A., Craft, P., Webb, S., Townsend, A., Kotasek, D.
Format: Journal Article
Published: Wiley-Blackwell Publishing Ltd. 2014
Subjects:
lapatinib/capecitabine
HER2-positive breast cancer
post-trastuzumab
Online Access:http://hdl.handle.net/20.500.11937/23969

Internet

http://hdl.handle.net/20.500.11937/23969

Similar Items